Zevra Therapeutics Analyst Price Targets - Benzinga

Zevra Therapeutics Inc

ZVRANASDAQ

Trade with Public

Trade with Public

$12.30

0.241.99%

al cierre: Sep 2, 5:00 PM EST

$12.20

-0.0965-0.78%

After hour: 4:32 PM EST

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Zevra Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Zevra Therapeutics (ZVRA).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

3S.Buy

8Buy

Consensus RatingBuy# Analysts11Avg. Consensus PT$24Upside to Avg. PT+92.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 20, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$26
Aug 7, 2026	Guggenheim	Eddie Hickman	PT Cut	Buy	$24→$23
Aug 6, 2026	Citizens	Jason N. Butler	PT Raise	Market Outperform	$25→$28
Jul 27, 2026	Canaccord Genuity	Sumant Kulkarni	PT Cut	Buy	$29→$20
Jul 27, 2026	Guggenheim	Eddie Hickman	PT Cut	Buy	$29→$24
Jul 27, 2026	BTIG	Kambiz Yazdi	PT Cut	Buy	$27→$24
Jun 23, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$26
Jun 11, 2026	Canaccord Genuity	Sumant Kulkarni	Maintained	Buy	$29
Jun 10, 2026	Maxim Group	Jason McCarthy	PT Raise	Buy	$25→$35
Jun 10, 2026	Guggenheim	Eddie Hickman	PT Raise	Buy	$25→$29
Jun 9, 2026	BTIG	Kambiz Yazdi	PT Raise	Buy	$23→$27
Jun 9, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$24→$29
Jun 9, 2026	Citizens	Jason Butler	PT Raise	Market Outperform	$18→$25
Jun 8, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$24→$34
May 8, 2026	Guggenheim	Eddie Hickman	PT Raise	Buy	$23→$25
Mar 16, 2026	BTIG	Kambiz Yazdi	Initiate	Buy	$23
Nov 6, 2025	Canaccord Genuity	Sumant Kulkarni	PT Cut	Buy	$25→$24
Nov 6, 2025	Cantor Fitzgerald	Kristen Kluska	PT Cut	Overweight	$29→$24
Aug 13, 2025	JMP Securities	Jason N. Butler	PT Cut	Market Outperform	$19→$18
Jul 10, 2025	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$25→$29

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and maintains $26 price target.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $24 to $23.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $28

Citizens analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and raises the price target from $25 to $28.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $20

Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $29 to $20.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $29 to $24.

Benzinga Newsdesk

Ford To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Monday

Wall Street analysts changed outlook on top names. See all rating changes on Benzinga's analyst ratings page for F, RIVN, TSM, ZVRA, ARWR, VZ, HBAN, GM, SAP, and CHTR.

Avi Kapoor